NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02204644,The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML,https://clinicaltrials.gov/study/NCT02204644,,COMPLETED,"A study to observe the efficacy and the safety of Flumatinib vs Imatinib as first line treatment in patients with newly diagnosed chronic phase chronic myelogenous leukemia.

Randomized,Open Label,Control",NO,"CML, CML-CP,MMR,TKI",DRUG: Flumatinib 600mg qd|DRUG: Imatinib 400mg qd,"SIX-month major molecular response rate, six months","major molecular response rate, 3 months, 9 months and 12 months",,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,400,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,HS-10096-301,2014-06,2017-06,2017-12,2014-07-30,,2018-02-27,"Hospital of Blood Diseases, Chinese Academy of Medical Sciences, Tianjin, Tianjin, 300020, China",
